| Literature DB >> 33246173 |
Vivek K Bajpai1, Sonam Sonwal2, Seung-Kyu Hwang2, Shruti Shukla3, Imran Khan4, Debasish Kumar Dey5, Lei Chen6, Jesus Simal-Gandara7, Jianbo Xiao8, Yun Suk Huh9, Young-Kyu Han10.
Abstract
Understanding how the natural products structural diversity interacts with cellular metabolism and infectious disease targets remains a challenge. Inflammation is an important process in the human healing response in which the tissues respond to injuries induced by many agents, including pathogens. In recent years, several drugs derived from plant products have been developed, and current drug research is actively investigating the pharmacotherapeutic role of natural products in advanced multimodal inflammatory disease targeting. Sugiol, a diterpenoid, can act as an antimicrobial, antioxidant, anti-inflammatory, anti-carcinoma, antiviral, and cardiovascular agent. Until now, there have been no updates on the pharmacotherapeutic advancement of sugiol. Herein, we correlate the diverse molecular pathways in disease prevention involving sugiol. We also discuss the origins of its structural diversity and summarize new research directions toward exploring its novel effective future uses. Despite much evidence of its efficacy and safety, the sugiol has not yet been approved as a therapeutic agent due to its low bioavailability, and insolubility in an aqueous environment. The aim of this review is to renew and update noteworthy information on the pharmacotherapeutic characteristics of sugiol to approach different advanced strategies employed in the context of natural nurturing-based biomedicine.Entities:
Keywords: Anticancer; Diterpenoid; Natural products; Pharmaco therapeutic; Sugiol
Year: 2020 PMID: 33246173 DOI: 10.1016/j.phrs.2020.105313
Source DB: PubMed Journal: Pharmacol Res ISSN: 1043-6618 Impact factor: 7.658